General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-14 | 2024-03 | -0.06 | -0.05 | 0.01 | 16.67% |
2024-02-14 | 2023-12 | 0.13 | -0.06 | -0.19 | -146.15% |
2023-12-29 | 2023-09 | 0 | -0.07 | N/A | N/A |
2023-08-14 | 2023-06 | -0.06 | -0.06 | N/A | N/A |
2023-05-12 | 2023-03 | -0.04 | -0.07 | -0.03 | -75.00% |
2023-02-10 | 2022-12 | 0 | -0.04 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-04-02 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-28 | HC Wainwright & Co. | Upgrade | Buy | |
2022-01-17 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-09-26 | HOLUBIAK MYRON Z | Chief Executive Officer | 1.99M | Purchase |
2019-09-26 | MAZUR LEONARD L | Officer, Director and Beneficial Owner | 10.26M | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 8.08M | 9.70M | 5.09% |
2023-06-29 | Vanguard Group Inc | 6.68M | 8.02M | 4.21% |
2023-06-29 | Geode Capital Management, LLC | 2.61M | 3.13M | 1.64% |
2023-06-29 | State Street Corporation | 2.11M | 2.53M | 1.33% |
2023-06-29 | Northern Trust Corporation | 1.03M | 1.23M | 0.65% |
2023-06-29 | Nuveen Asset Management, LLC | 484.65K | 581.58K | 0.31% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.00M | 4.80M | 2.52% |
2023-08-30 | iShares Russell 2000 ETF | 2.76M | 2.52M | 1.74% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.93M | 2.31M | 1.21% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.08M | 1.07M | 0.68% |
2023-08-30 | iShares Russell 2000 Value ETF | 948.68K | 865.39K | 0.60% |
2023-05-30 | Fidelity Extended Market Index Fund | 701.67K | 813.93K | 0.44% |
Split | Date |
---|---|
1 : 15 | 2017-06-09 |
$CTXR- Things are in the works! The market rxn has NOTHING to do with what’s going on internally, behind the scenes. This is still gonna happen folks Be patient
$CTXR- WOW…I must be dreaming…I finally lived long enough to hear some POSITIVE words from DL!! Today is the day!!!🤭
$CTXR- Today is the day. Amen
$CTXR-Those who are holding shares are gonna get a big bag any day now
$CTXR- A re-post/reminder??? This appeared today on Yahoo finance, but it’s not on the CTXR web site. A bit confusing…
https://finance.yahoo.com/news/citius-ctxr-posts-top-line-135701798.html
$CTXR- FYI….the investors conferences are both in NYC. That’s just a short train or car ride up the NJ Turnpike from CTXR headquarters in Cranford, NJ. No planes are involved
$CTXR- delisting is NOT going to happen! They have a contingency plan.
$CTXR- Edward.DR…..there IS NO Phase4 drug trial!! lol. Phase4 is sometimes initiated AFTER a drug is FULLY APPROVED by the FDA and has been marketed to the public. It simply calculates data on possible side effects or adverse reactions once it is being marketed to the public. By then, CTXR will have already skyrocketed!!
$CTXR- They had to do this small dilution as “an insurance policy”. Everything is still on course. The number of shares and the amount of $$ involved with this is PEANUTS considering the hundreds of millions or several billions of revenue that are coming soon. Once their milestones begin to hit (in the next few months or so), the pps is likely to go up to $8-$10. It’s gonna happen folks so BE PATIENT!
$CTXR- This is still a no brainer BUY. HUGE potential!! https://dwinnex.com/closing-figures-unveiled-citius-pharmaceuticals-inc-ctxr-drop-6-34-closes-at-0-75/
$CTXR- Y’all can swing trade all you want and make a fast buck. But CTXR is gonna make it happen and EXPLODE in the near future. Don’t worry. Be patient…
$CTXR- GREAT things—ALL POSITIVE—all lined up for the next few months.
$CTXR- It is clear that the scientific community has tremendous interest—and confidence—that Lymphir is a worthy and valid drug. Multiple studies have been initiated at major universities and cancer research centers to combine Lymphir with other drugs in an effort to help combat various types of lymphomas and boost their effects. As these studies continue to evolve, the additional exposure of Lymphir will only help the Citius spinoff company (and its shareholders), while potentially helping scores of patients who suffer with these horrible diseases.
$CTXR- ALL POSITIVE news at the conference!!
$CTXR- approx 26,700 premarket. There was even some action at $1.08Could be an awesome day!
$CTXR- Let’s GO already! https://www.setenews.com/2024/04/03/prepare-yourself-for-liftoff-citius-pharmaceuticals-inc-ctxr/